FindTrial
Sign In

A seroprevalence study of COVID-19 in IBD patients

A seroprevalence study of COVID-19 in IBD patients - A seroprevalence study of COVID-19 in IBD patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000040838
Enrollment
2000
Registered
2020-07-01
Start date
2020-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory bowel disease (IBD) patients in the broad sense

Interventions

IBD patients healthy control

Sponsors

Hyogo College of Medicine, Center for Inflammatory Bowel Disease, Division of Internal Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Broad IBD patients (ulcerative colitis, Crohn's disease, Behcet's disease, MEFV gene-related enterocolitis, SLCO2A1 gene-related enterocolitis, IBD unclassified)

Exclusion criteria

Exclusion criteria: patients with active COVID-19

Design outcomes

Primary

MeasureTime frame
a positive rate of an anti-SARS-CoV-2 IgG antibody in serum of IBD patient—

Countries

Japan

Contacts

Public ContactKenji Watanabe

Hyogo College of Medicine Center for Inflammatory Bowel Disease, Division of Internal Medicine

kenjiw1779@gmail.com0798456663

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026